“…For example, examined using levels of multiple metabolites within the same hippocampal VOI, Rupsingh et al (2011) found that the accuracy of discriminating clinical AD from HC was 71% using NAA / Cr , 80% using Glu , and 94% using a combination of the quantitative NAA / Cr , Glu , and mI [102]. Similarly, in the study by Wang and others (2009), the increased mI / NAA in AD in both hippocampal and posterior cingulate VOIs was used for AD and HC classification; a better performance was obtained than when using data from a single VOI [116], as also reported by Azevedo and colleagues (2008) using a lower field [127]. These observations linked the uneven spatial expression to progressive distortion of brain structures compromised by the disease [11], suggesting some potential of MRS-based evaluation of multiple neurochemicals, and of combining metabolite data acquired from more than one brain region.…”